Amneal Pharmaceuticals Inc. has announced that its subsidiary, Amneal Pharmaceuticals LLC, has priced a private offering of $600 million in senior secured notes due 2032, with an interest rate of 6.875%. The offering was adjusted down from an initially planned $750 million, in conjunction with an increase in the term loan facility. Concurrently, Amneal plans to borrow $2.1 billion in new seven-year term B loans under a new term loan facility. The proceeds from these financial activities will be used to refinance existing term B loans, repay outstanding amounts under the ABL facility, and cover related expenses. The notes, offered at 100% of their principal amount, are expected to close on August 1, 2025, subject to customary closing conditions.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。